Upregulation of MicroRNA-122 by Farnesoid X Receptor Suppresses the Growth of Hepatocellular Carcinoma Cells

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2015 Aug 26

PMID 26302777

Citations 28

Authors

Jialin He

Kai Zhao

Lu Zheng

Zhizhen Xu

Wei Gong

Shan Chen

Xiaodong Shen

Gang Huang

Min Gao

Yijun Zeng

Yan Zhang

Fengtian He

Affiliations

Soon will be listed here.

Abstract

Background: microRNA-122 (miR-122) is the most abundant and specific miRNA in the liver. It acts as an important tumor suppressor in hepatocellular carcinoma (HCC) through regulating its target genes, but details of its own regulation are largely unknown. Farnesoid X receptor (FXR), a transcription factor with multiple functions, plays an important role in protecting against liver carcinogenesis, but it is unclear whether the anti-HCC effect of FXR is involved in the regulation of miR-122.

Methods: The levels of miR-122 and FXR in HCC tissues and cell lines were examined by quantitative real-time PCR (qRT-PCR). qRT-PCR was also used to detect the expression of miR-122 target genes at mRNA level, while Western blotting was used to analyze that of their protein products. The effect of FXR on the transcriptional activity of miR-122 promoter was evaluated by a luciferase reporter assay. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay were performed to identify the FXR binding site within miR-122 promoter region. The cell proliferation was analyzed by a CCK-8 assay. The influence of FXR on tumor growth and miR-122 expression in vivo was monitored using HCC xenografts in nude mice.

Results: The expression of FXR was positively correlated with that of miR-122 in HCC tissues and cell lines. Activation of FXR in HCC cells upregulated miR-122 expression and in turn downregulated the expression of miR-122 target genes including insulin-like growth factor-1 receptor and cyclin G1. FXR bound directly to the DR2 element (-338 to -325) in miR-122 promoter region, and enhanced the promoter's transcriptional activity. Functional experiments showed that the FXR-mediated upregulation of miR-122 suppressed the proliferation of HCC cells in vitro and the growth of HCC xenografts in vivo.

Conclusions: miR-122 is a novel target gene of FXR, and the upregulation of miR-122 by FXR represses the growth of HCC cells, suggesting that FXR may serve as a key transcriptional regulator for manipulating miR-122 expression, and the FXR/miR-122 pathway may therefore be a novel target for the treatment of HCC.

Citing Articles

A Narrative Review: Immunometabolic Interactions of Host-Gut Microbiota and Botanical Active Ingredients in Gastrointestinal Cancers.

Li S, Feng W, Wu J, Cui H, Wang Y, Liang T Int J Mol Sci. 2024; 25(16).

PMID: 39201782 PMC: 11354385. DOI: 10.3390/ijms25169096.

The significance of lipid metabolism reprogramming of tumor-associated macrophages in hepatocellular carcinoma.

Xie Q, Zeng Y, Zhang X, Yu F Cancer Immunol Immunother. 2024; 73(9):171.

PMID: 38954021 PMC: 11220057. DOI: 10.1007/s00262-024-03748-9.

Supplementation of Mangiferin to a High-Starch Diet Alleviates Hepatic Injury and Lipid Accumulation Potentially through Modulating Cholesterol Metabolism in Channel Catfish ().

Zheng Y, Lu Q, Cao J, Liu Y, Liu H, Jin J Antioxidants (Basel). 2024; 13(6).

PMID: 38929161 PMC: 11200457. DOI: 10.3390/antiox13060722.

Dysbiosis: The first hit for digestive system cancer.

Mei S, Deng Z, Chen Y, Ning D, Guo Y, Fan X Front Physiol. 2022; 13:1040991.

PMID: 36483296 PMC: 9723259. DOI: 10.3389/fphys.2022.1040991.

Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma.

Chun K Pharmaceutics. 2022; 14(7).

PMID: 35890276 PMC: 9316959. DOI: 10.3390/pharmaceutics14071380.

References

Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu C . Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007; 67(13):6092-9. DOI: 10.1158/0008-5472.CAN-06-4607. View

Ma L, Liu J, Shen J, Liu L, Wu J, Li W . Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther. 2010; 9(7):554-61. DOI: 10.4161/cbt.9.7.11267. View

Fukuhara T, Matsuura Y . Role of miR-122 and lipid metabolism in HCV infection. J Gastroenterol. 2012; 48(2):169-76. PMC: 3698423. DOI: 10.1007/s00535-012-0661-5. View

Wang Y, Chen W, Wang M, Yu D, Forman B, Huang W . Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008; 48(5):1632-43. PMC: 3056574. DOI: 10.1002/hep.22519. View

Li H, Fu X, Chen Y, Hong Y, Tan Y, Cao H . Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology. 2005; 128(7):2029-41. DOI: 10.1053/j.gastro.2005.03.001. View

Makishima M, Okamoto A, REPA J, Tu H, Learned R, Luk A . Identification of a nuclear receptor for bile acids. Science. 1999; 284(5418):1362-5. DOI: 10.1126/science.284.5418.1362. View

Forman B, Goode E, Chen J, Oro A, Bradley D, Perlmann T . Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995; 81(5):687-93. DOI: 10.1016/0092-8674(95)90530-8. View

Deuschle U, Schuler J, Schulz A, Schluter T, Kinzel O, Abel U . FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One. 2012; 7(10):e43044. PMC: 3467263. DOI: 10.1371/journal.pone.0043044. View

Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L . Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology. 2011; 55(3):730-41. DOI: 10.1002/hep.24809. View

10.

Claudel T, Sturm E, Duez H, Torra I, Sirvent A, Kosykh V . Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest. 2002; 109(7):961-71. PMC: 150929. DOI: 10.1172/JCI14505. View

11.

Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T . Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002; 12(9):735-9. DOI: 10.1016/s0960-9822(02)00809-6. View

12.

Bai S, Nasser M, Wang B, Hsu S, Datta J, Kutay H . MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009; 284(46):32015-27. PMC: 2797273. DOI: 10.1074/jbc.M109.016774. View

13.

Wu X, Wu S, Tong L, Luan T, Lin L, Lu S . miR-122 affects the viability and apoptosis of hepatocellular carcinoma cells. Scand J Gastroenterol. 2009; 44(11):1332-9. DOI: 10.3109/00365520903215305. View

14.

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

15.

Schickel R, Boyerinas B, Park S, Peter M . MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008; 27(45):5959-74. DOI: 10.1038/onc.2008.274. View

16.

Ohtsuka T, Ryu H, Minamishima Y, Ryo A, Lee S . Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene. 2003; 22(11):1678-87. DOI: 10.1038/sj.onc.1206306. View

17.

Okamoto K, Li H, Jensen M, Zhang T, Taya Y, Thorgeirsson S . Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell. 2002; 9(4):761-71. DOI: 10.1016/s1097-2765(02)00504-x. View

18.

Su H, Ma C, Liu J, Li N, Gao M, Huang A . Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol. 2012; 303(11):G1245-53. PMC: 3532459. DOI: 10.1152/ajpgi.00439.2011. View

19.

Filipowicz W, Bhattacharyya S, Sonenberg N . Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet. 2008; 9(2):102-14. DOI: 10.1038/nrg2290. View

20.

Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W . Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006; 99(3):671-8. PMC: 3033198. DOI: 10.1002/jcb.20982. View